# Bicycle Therapeutics

Source: https://onco.cc/companies/bicycle-therapeutics/  
OnCo record `bicycle-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Inventor of bicyclic peptide drug conjugates; its lead Nectin-4 conjugate was deprioritised in 2026 after regulatory feedback.

## Summary

Bicycle Therapeutics, based in Cambridge in the United Kingdom and listed as BCYC, is the inventor of bicyclic peptide drug conjugates, a class of small, synthetic alternatives to antibody-drug conjugates. Its lead Nectin-4 conjugate, zelenectide pevedotin, or BT8009, was deprioritised in 2026 after regulatory feedback, BT5528 targets EphA2, and its Bicycle radio-conjugates are partnered with Bayer and Novartis in radiopharmaceuticals. OnCo links it to bladder and urothelial cancer, to the zelenectide pevedotin drug record, and to the peptide-drug and small-molecule-drug conjugate technology. Whether bicyclic peptides find their place as radiopharmaceutical carriers rather than as cytotoxic conjugates is the question the 2026 decision poses. Zelenectide pevedotin has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Cambridge
- Type: biotech
- Website: https://www.bicycletherapeutics.com
- Ticker: BCYC

## Sources

- Official website: https://www.bicycletherapeutics.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Peptide-drug & small-molecule-drug conjugates](https://onco.cc/technologies/peptide-drug-conjugate/)
- drugs: [Zelenectide pevedotin](https://onco.cc/drugs/zelenectide-pevedotin/)
- trials: [A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07450859/), [Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression](https://onco.cc/trials/nct04180371/), [Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression](https://onco.cc/trials/nct05163041/), [Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies](https://onco.cc/trials/nct04561362/), [Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)](https://onco.cc/trials/nct06225596/), [Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer](https://onco.cc/trials/nct06840483/), [Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06933329/)
- companies: [Novartis Venture Fund](https://onco.cc/companies/novartis-venture-fund/), [SV Health Investors](https://onco.cc/companies/sv-health-investors/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- roadmaps: [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/bicycle-therapeutics.json